Icarus Therapeutics - The Next Horizon

Advancing the Future of Clinical Trial Enrollment

Join Icarus Therapeutics for dinner and drinks, an evening of company updates, strategic vision, and investment opportunity as we share our progress and vision for transforming clinical trial enrollment.

Approximately 80% of clinical trials fail to recruit enough participants on time, contributing to delays, higher costs, and preventable research waste. For patients, these delays can postpone access to potentially life-saving treatments and slow the development of therapies for serious diseases.

Join us to explore how better patient identification, data integration, and patient-provider matching can help remove the enrollment bottleneck and accelerate clinical research with our AI-Enabled site native clinical trial platform.

The evening will feature the Icarus New York team, Dr. Nilay Shah, Brain Research Institute of New York and New Jersey, New York, NY, Dr. Julio Vega, board-certified Neurologist and board-eligible Interventional Pain Specialist, and a Partner at BonLeven Healthcare, alongside CTO Larry Yuan (Managing Director of Digital Transformation at GrowthCurve Capital, formerly of Meta, Yahoo, and LinkedIn) and CMO Dr. Bob Carr (GSK).

Icarus Co-Founder and CEO Nate Hughes (HealthVerity, Allucent, and CTI Clinical Trials) will deliver a brief presentation exploring the evolving landscape of clinical trial enrollment, including patient data integration, data provenance at clinical research sites, and emerging trends in patient-provider matching to accelerate patient recruitment and improve enrollment outcomes. He will also discuss future Icarus plans, such as piloting the solution at sites.

Discover how Icarus Therapeutics is advancing a smarter, more connected approach to clinical trial enrollment—and learn about the investment opportunity to help bring this vision to life.